Lenferink AE - Search Results

1

Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells.

Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT, Arteaga CL. Kurokawa H, et al. Among authors: lenferink ae. Cancer Res. 2000 Oct 15;60(20):5887-94. Cancer Res. 2000. PMID: 11059787

2

Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice.

Lenferink AE, Simpson JF, Shawver LK, Coffey RJ, Forbes JT, Arteaga CL. Lenferink AE, et al. Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9609-14. doi: 10.1073/pnas.160564197. Proc Natl Acad Sci U S A. 2000. PMID: 10931950 Free PMC article.

3

ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.

Lenferink AE, Busse D, Flanagan WM, Yakes FM, Arteaga CL. Lenferink AE, et al. Cancer Res. 2001 Sep 1;61(17):6583-91. Cancer Res. 2001. PMID: 11522658

4

ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells.

Muraoka RS, Lenferink AE, Law B, Hamilton E, Brantley DM, Roebuck LR, Arteaga CL. Muraoka RS, et al. Among authors: lenferink ae. Mol Cell Biol. 2002 Apr;22(7):2204-19. doi: 10.1128/MCB.22.7.2204-2219.2002. Mol Cell Biol. 2002. PMID: 11884607 Free PMC article.

5

Tyrosine kinase inhibitors: rationale, mechanisms of action, and implications for drug resistance.

Busse D, Yakes FM, Lenferink AE, Arteaga CL. Busse D, et al. Among authors: lenferink ae. Semin Oncol. 2001 Oct;28(5 Suppl 16):47-55. doi: 10.1016/s0093-7754(01)90282-9. Semin Oncol. 2001. PMID: 11706396 Review.

6

Cyclin-dependent kinase inhibitor p27(Kip1) is required for mouse mammary gland morphogenesis and function.

Muraoka RS, Lenferink AE, Simpson J, Brantley DM, Roebuck LR, Yakes FM, Arteaga CL. Muraoka RS, et al. Among authors: lenferink ae. J Cell Biol. 2001 May 28;153(5):917-32. doi: 10.1083/jcb.153.5.917. J Cell Biol. 2001. PMID: 11381079 Free PMC article.

7

Investigation of three new mouse mammary tumor cell lines as models for transforming growth factor (TGF)-beta and Neu pathway signaling studies: identification of a novel model for TGF-beta-induced epithelial-to-mesenchymal transition.

Lenferink AE, Magoon J, Cantin C, O'Connor-McCourt MD. Lenferink AE, et al. Breast Cancer Res. 2004;6(5):R514-30. doi: 10.1186/bcr907. Epub 2004 Jul 6. Breast Cancer Res. 2004. PMID: 15318933 Free PMC article.

8

Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers.

Lenferink AE, Pinkas-Kramarski R, van de Poll ML, van Vugt MJ, Klapper LN, Tzahar E, Waterman H, Sela M, van Zoelen EJ, Yarden Y. Lenferink AE, et al. EMBO J. 1998 Jun 15;17(12):3385-97. doi: 10.1093/emboj/17.12.3385. EMBO J. 1998. PMID: 9628875 Free PMC article.

9

The EGF domain: requirements for binding to receptors of the ErbB family.

Van Zoelen EJ, Stortelers C, Lenferink AE, Van de Poll ML. Van Zoelen EJ, et al. Among authors: lenferink ae. Vitam Horm. 2000;59:99-131. doi: 10.1016/s0083-6729(00)59005-0. Vitam Horm. 2000. PMID: 10714238 Review.

10

Superagonistic behaviour of epidermal growth factor/transforming growth factor-alpha chimaeras: correlation with receptor routing after ligand-induced internalization.

Lenferink AE, Kramer RH, van Vugt MJ, Königswieser M, Di Fiore PP, van Zoelen EJ, van de Poll ML. Lenferink AE, et al. Biochem J. 1997 Nov 1;327 ( Pt 3)(Pt 3):859-65. doi: 10.1042/bj3270859. Biochem J. 1997. PMID: 9581567 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

37 results

Search Page

Filters